Caraco receives approval to market generic diabetes drug

Glipizide or Metformin HCl is indicated as initial therapy, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone. It is also indicated as second-line therapy when diet, exercise, and initial treatment with a sulfonylurea or metformin do not result in adequate glycemic control in patients with type 2 diabetes.

Daniel Movens, CEO of Caraco, said: “Our focus continues to be working towards expanding our product line effectively, including products that are already available generically in the market that potentially can add measurable value.”